# Safety, Pharmacodynamics, and Pharmacokinetics of Different Dosing Regimens of MK-8266 in Participants With Hypertension (MK-8266-008)

> **NCT01244035** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 31 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Treatment A
- **DRUG:** Treatment B
- **DRUG:** Treatment C
- **DRUG:** Treatment D
- **DRUG:** Treatment E
- **DRUG:** Treatment F

## Key facts

- **NCT ID:** NCT01244035
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08-19
- **Primary completion:** 2010-12-23
- **Final completion:** 2010-12-23
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2019-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01244035

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01244035, "Safety, Pharmacodynamics, and Pharmacokinetics of Different Dosing Regimens of MK-8266 in Participants With Hypertension (MK-8266-008)". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT01244035. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*